Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 17;12:1714. doi: 10.1038/s41467-021-21976-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 8 — a X-ray radiographs (up), H&E staining (middle), and TRAP staining (down) of tibias at 40 days after inoculation of PC-3 parental cells into the tibias. White arrows point to areas of bone lesions. Numbers at the top-left corner of X-ray radiographs are the Average Bone Lesion Score (ABLS) based on the degree of osteolysis. b The ratio of tumor area to total sample area of PC-3 parental cells in tibias under docetaxel and/or AMD3100 treatment. n = 6 tumors for the control or single treatment group and n = 8 tumors for the combined treatment group. c Statistical analyses of TRAP occurrence (oc) at the bone-tumor interface in bone samples bearing PC-3 parental cells treated with docetaxel and/or AMD3100. n = 6 tumors per group. d H&E staining (upper) and TRAP staining (lower) of tibias at 38 days (DU 145) or 43 days (PC-3) after inoculation of cells expressing KLF5^KR (KR) or KLF5^KQ (KQ). e The ratio of tumor area to total sample area of DU 145 (upper) and PC-3 (lower) cells expressing KLF5^KR (KR) or KLF5^KQ (KQ) in tibias under the treatments of docetaxel and/or AMD3100. For DU 145, n = 6 tumors for the control or single treatment group and n = 8 tumors for the combined treatment group. For PC-3, n = 8 tumors for each group. f Statistical analyses of TRAP occurrence (oc) at the bone-tumor interface in bone samples bearing DU 145 (up) and PC-3 (down) cells expressing different forms of KLF5 treated with docetaxel and/or AMD3100. For DU 145, n = 6 tumors per group. For PC-3, n = 8 tumors per group. B trabecular bone region, BM bone marrow region, T tumor region. Scale bar, 50 μm. Treatments with docetaxel (10 mg/kg twice a week via i.p.) and/or AMD3100 (3.5 mg/kg/day via i.p.) started at day 11 after tumor inoculation. Representative images shown in a and d are statistically analyzed in b, c and e, f, respectively. In panels b, c, e and f, data are shown in mean ± S.E.M. NS not significant; *p < 0.05; **p < 0.01; ***p < 0.001 (two-tailed Student’s t test). Source data are provided as a Source Data file.